Tailored Treatment Strategies in First Line Therapy for Ovarian Cancer Patients: A Critical Review of the Literature

被引:3
作者
Luvero, Daniela [1 ]
Angioli, Roberto [1 ,2 ]
Celoro, Federica [2 ]
Plotti, Francesco [1 ,2 ]
Terranova, Corrado [1 ,2 ]
Guzzo, Federica [1 ]
Cundari, Gianna Barbara [2 ]
Liparulo, Federico [2 ]
Verdone, Camilla [2 ]
Montera, Roberto [1 ,2 ]
机构
[1] Fdn Policlin Univ Campus Bio Med, Dept Gynecol, Via Alvaro del Portillo 200, I-00128 Rome, Italy
[2] Univ Campus Bio Med, Dept Med & Surg, Res Unit Gynecol, Via Alvaro del Portillo 21, I-00128 Rome, Italy
关键词
ovarian cancer; PARP inhibitors; maintenance therapy; bevacizumab; PHASE-III TRIAL; MAINTENANCE OLAPARIB; RANDOMIZED TRIAL; BRCA MUTATION; OPEN-LABEL; STAGE-III; BEVACIZUMAB; CHEMOTHERAPY; RECURRENT; CISPLATIN;
D O I
10.3390/ph17060778
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: Ovarian cancer (OC) is a significant cause of cancer-related mortality in women globally, with a five-year survival rate of approximately 49%. Standard therapy involves cytoreductive surgery followed by chemotherapy. Its poor prognosis has driven interest in alternative therapies such as targeted molecular agents like bevacizumab and poly (ADP-ribose) polymerase inhibitors (PARPi). Materials and Methods: This review systematically searched PubMed from January 2018 to December 2023 for studies on PARPi in OC. Emphasis was on identifying relevant Phase III trials, extracting data on study design, patient demographics, and outcomes. Special focus was on assessing PARPi efficacy, safety, impact on quality of life, and ongoing trials, including those on Clinicaltrials.gov. Results: The efficacy of PARPi in first-line therapy for OC has been extensively studied. Trials like SOLO-1, PRIMA, and ATHENA-MONO have demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS), particularly in patients with BRCA mutations. Additionally, the combination of PARPi with other agents like bevacizumab has shown promising results in extending PFS. However, PARPi treatment is associated with various adverse effects, including hematologic toxicities like anemia, thrombocytopenia, and neutropenia. While most adverse events are manageable, some patients may require dose adjustments or discontinuation of treatment. Importantly, PARPi maintenance therapy has not adversely affected health-related quality of life (HRQoL), with studies reporting similar HRQoL scores between PARPi-treated and placebo-treated patients. Conclusions: PARPi offer effective treatment with manageable side effects, suitable even for medically fragile patients. Individualized dosing can optimize benefits while minimizing adverse events. Exploring diverse treatment approaches, particularly in patients with limited life expectancy or high disease burden, could improve outcomes. Ongoing research is investigating alternative therapies and combinations to broaden treatment options. Combining bevacizumab with PARPi may be justified for first-line and recurrent maintenance therapy. Regardless of mutational status, PARPi should be considered for maintenance therapy in newly diagnosed advanced OC. Platinum sensitivity remains crucial for treatment decisions and predicting survival outcomes.
引用
收藏
页数:12
相关论文
共 45 条
  • [1] Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
    Aghajanian, Carol
    Goff, Barbara
    Nycum, Lawrence R.
    Wang, Yan V.
    Husain, Amreen
    Blank, Stephanie V.
    [J]. GYNECOLOGIC ONCOLOGY, 2015, 139 (01) : 10 - 16
  • [2] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
    Aghajanian, Carol
    Blank, Stephanie V.
    Goff, Barbara A.
    Judson, Patricia L.
    Teneriello, Michael G.
    Husain, Amreen
    Sovak, Mika A.
    Yi, Jing
    Nycum, Lawrence R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) : 2039 - 2045
  • [3] Epidemiology and risk factors for ovarian cancer
    Ali, Aus Tariq
    Al-ani, Osamah
    Al-ani, Faisal
    [J]. MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY, 2023, 22 (02): : 93 - 104
  • [4] Quality-adjusted time without symptom or toxicity (QA-TWiST) and quality-adjusted progression-free survival (QA-PFS) of first-line (1L) maintenance niraparib in patients with advanced ovarian cancer (OC): Results from the PRIMA trial
    Barretina-Ginesta, M-P.
    Monk, B. J.
    Han, S.
    Pothuri, B.
    Auranen, A.
    Chase, D.
    Lorusso, D.
    Anderson, C.
    Abadie-Lacourtoisie, S.
    Cloven, N.
    Braicu, E. I.
    Amit, A.
    Redondo, A.
    Shah, R.
    Kebede, N.
    Hawkes, C.
    Gupta, D.
    Woodward, T.
    O'Malley, D. M.
    Gonzalez Martin, A. J.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S736 - S737
  • [5] Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
    Burger, Robert A.
    Brady, Mark F.
    Bookman, Michael A.
    Fleming, Gini F.
    Monk, Bradley J.
    Huang, Helen
    Mannel, Robert S.
    Homesley, Howard D.
    Fowler, Jeffrey
    Greer, Benjamin E.
    Boente, Matthew
    Birrer, Michael J.
    Liang, Sharon X.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) : 2473 - 2483
  • [6] Patterns and progress in ovarian cancer over 14 years
    Chan, John K.
    Cheung, Michael K.
    Husain, Amreen
    Teng, Nelson N.
    West, Dee
    Whittemore, Alice S.
    Berek, Jonathan S.
    Osann, Kathryn
    [J]. OBSTETRICS AND GYNECOLOGY, 2006, 108 (03) : 521 - 528
  • [7] clinical trials, Fluzoparib Combined with Bevacizumab in PSROC Previously Treated with PARPi
  • [8] clinicaltrials, STUDY EVALUATING EFF
  • [9] clinicaltrials, Niraparib and Bevacizumab Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated with a PARP Inhibitor (NIRVANA-R)
  • [10] Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
    Coleman, Robert L.
    Brady, Mark F.
    Herzog, Thomas J.
    Sabbatini, Paul
    Armstrong, Deborah K.
    Walker, Joan L.
    Kim, Byoung-Gie
    Fujiwara, Keiichi
    Tewari, Krishnansu S.
    O'Malley, David M.
    Davidson, Susan A.
    Rubin, Stephen C.
    DiSilvestro, Paul
    Basen-Engquist, Karen
    Huang, Helen
    Chan, John K.
    Spirtos, Nick M.
    Ashfaq, Raheela
    Mannel, Robert S.
    [J]. LANCET ONCOLOGY, 2017, 18 (06) : 779 - 791